Skip Navigation

European Heart Journal 2003 24(21):1901-1902; doi:10.1016/j.ehj.2003.08.010
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Böger, R. H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Böger, R. H
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

When the endothelium cannot say ‘NO’ anymore

ADMA, an endogenous inhibitor of NO synthase, promotes cardiovascular disease

Rainer H Böger*

Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center of Experimental Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany

* Correspondence to: +49 42803 9759; fax: +49 42803 9757
E-mail address: boeger@uke.uni-hamburg.de

Received 19 August 2003; accepted 28 August 2003

The first 10% of the full text of this article appears below.

See doi:10.1016/j.ehj.2003.08.013 for the article to which this editorial refers

The endothelium is one of the biggest organ systems in our body. This is not so apparent on first view, as it is spread throughout the body mostly in tiny arterioles and capillaries. If you should be asked to define the endothelium's ‘personality’, you would certainly come to the notion that this organ is characterized by a negative attitude: If vasoconstrictors attempt to constrict our arteries, the endothelium says ‘NO’; if platelets tend to adhere to the vessel wall, the endothelium says NO’; if monocytes try to invade the vascular wall by penetrating the endothelial lining, the endothelium says ‘NO’ again; finally, if oxygen radicals sound the charge against the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention
Tse-Min Lu, Yu-An Ding, Shing-Jong Lin, Wen-Shin Lee, and Ho-Charng Tai
EHJ 2003 24: 1912-1919. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 Clin. Chem.Home page
R. Maas, F. Schulze, J. Baumert, H. Lowel, K. Hamraz, E. Schwedhelm, W. Koenig, and R. H. Boger
Asymmetric Dimethylarginine, Smoking, and Risk of Coronary Heart Disease in Apparently Healthy Men: Prospective Analysis from the Population-Based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg Study and Experimental Data
Clin. Chem., April 1, 2007; 53(4): 693 - 701.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
Z. Yang and X.-F. Ming
Recent advances in understanding endothelial dysfunction in atherosclerosis.
Clin. Med. Res., March 1, 2006; 4(1): 53 - 65.
[Abstract] [Full Text] [PDF]

Home page
 Vasc MedHome page
R. H Boger
Asymmetric dimethylarginine (ADMA) modulates endothelial function - therapeutic implications
Vascular Medicine, August 1, 2003; 8(3): 149 - 151.
[PDF]